Lupski's Research into His Disease Paved Way Toward Personalized Medicine

[Guest guest]

Lupski's Research into His Disease Paved Way Toward Personalized Medicine

http://quest.mda.org/article/james-lupskis-research-his-disease-paved-way-toward\

-personalized-medicine

Lupski's story has all the elements of a good sci-fi tale: a research

scientist determined to uncover the cause of his own genetic disease, a friend

and colleague who's also an intrepid gene hunter, and a futuristic technology

that not only pinpoints the molecular cause of the research scientist's disease,

but also opens the door to a new era of personalized medicine.

But in this case, it's not science fiction. It's science fact.

The research scientist is Lupski, Cullen Professor and vice chair of

molecular and human genetics at Baylor College of Medicine in Houston. The

disease is Charcot-Marie-Tooth (CMT), which affects Lupski and several family

members. The colleague and gene hunter is Gibbs, director of the Baylor

Human Genome Sequencing Center.

And the technology that's positioned to change the field of medicine is the

ability to reliably (and ever more affordably) produce a readout of an

individual's entire genetic blueprint, or DNA.

Lupski, 53, grew up in Hicksville, N.Y., one of four (out of eight) siblings

found to have CMT, a disease of the peripheral nerves that causes gradual loss

of strength and sensation in the feet and ankles, lower legs, and the hands and

forearms.

A series of surgeries on his feet and ankles after the age of 15 caused him to

miss his sophomore and junior years of high school. In addition to studying at

home for a few hours a day, Lupski read books that fostered his interest in

science, genetics and medicine. His surgeon became his mentor and encouraged him

to go into medicine.

At New York University, Lupski earned a doctorate in biochemistry and molecular

biology, and an M.D. He then received clinical training in Houston and board

certifications in both pediatrics and medical genetics. Among other professional

pursuits, he studied the disease he'd lived with all his life.

The first find

Lupski received MDA research funding beginning in the late 1980s and lasting

through 2003. In 1991, he and his team identified the first gene to be

associated with CMT, PMP22. The gene is responsible for approximately 70 percent

of CMT cases.

" MDA was incredibly supportive of our research, " Lupski recalled, " and that is

what helped find the first CMT mutation, the PMP22 duplication. "

With continued MDA support, Lupski's team identified a handful of other genes

associated with CMT, including the periaxin (PRX) gene and EGR2 gene.

The MDA funding he received, Lupski said, " was very helpful for getting a lot of

the original CMT research up and running — definitely a positive. "

One negative, however, was that none of the various genes discovered to be

associated with CMT (there are now more than 20), proved to be the culprit in

Lupski's disease. (For more on Lupski's early efforts to find the cause of his

CMT, see CMT Researchers Tell Their Own Story, Quest, Volume 1, Number 2, 1994.)

What next?

The first complete, three-billion-letter, individual human genome was published

in September 2007, a feat that was soon followed by efforts to sequence the

genomes of people of different nationalities in order to discern genetic

variations among them. Gibbs worked with Lupski to prove that sequencing

an individual's genome could pinpoint the gene or genes responsible for disease.

Lupski and his friend Gibbs of the Baylor Human Genome Sequencing Center

began discussing what should come next. The two considered sequencing the genome

of somebody with a disease as a means of determining whether the technology was

robust enough to spot the clinically important gene or genes in the process.

" The real test was, could you find the diseased gene out of a whole genome? And

choosing Charcot-Marie-Tooth disease was obvious, because it was my interest for

many, many years, but also because we knew enough about the biology to be able

to interpret the sequence. "

In the course of talks with Gibbs, Lupski commented that he still hadn't found

the cause of his own CMT. " said, `Well, why don't we do your genome?'

And I was happy to have it done, " Lupski said.

'Shotgunning' the genome

When Lupski and Gibbs began their study, the standard approach for genome

sequencing involved mapping small sections of DNA, " cloning " them (creating

copies) and assembling them into ever larger sections, and then putting all the

sections together.

Lupski and Gibbs instead took a route referred to as " shotgunning the genome, "

devised by biologist and entrepreneur J. Craig Venter. (Venter, founder and

president of the nonprofit J. Craig Venter Institute, made headlines this year

when researchers at the Institute announced they had created the first

self-replicating, synthetic bacterial cell capable of self-reproduction and

controlled by the synthetic genome.)

" Let's say the human genome is a 23-volume encyclopedia, and each volume is like

one human chromosome, " Lupski said. The accepted approach used to be to take

each volume separately, a process that equates to separating the chromosomes,

separating the material into smaller clones, and then separating it further

before building it back up.

" Venter's shotgun approach was, `Let's just take the stuff from the paper

shredder.' That is, shred all 23 volumes into sentences, or snippets of DNA, and

then let the computer figure out how those sentences go together to build the

entire genome. "

In sequencing his genome, Lupski said, " We just shotgunned. We took the entire

genome and just blew it to bits, and took little sequencing reads, only about 50

to 100 nucleotides [DNA base building blocks] each, so it wouldn't even be a

full sentence, it might be more like five words of 10 letters each. "

They put it into the computer and let the computer match it to the reference

human genome sequence. Finally, they used the differences between Lupski's

genome and the reference genome to determine which variation was responsible for

Lupski's CMT.

Personal victory

The pending outcome was a big unknown, Lupski said, but " in the end we hit

gold. "

Lupski's team published results online March 10, 2010, in the New England

Journal of Medicine. They concluded that " whole-genome sequencing can identify

clinically relevant variants and provide diagnostic information " that can help

physicians care for their patients.

Lupski's CMT, and that of his siblings, turned out to be the result of mutations

in a gene called SH3TC2. The original identification of this gene as one

associated with CMT actually had come earlier, from a study conducted by a

multinational team led by Jan Senderek and published in the American Journal of

Human Genetics, October 21, 2003.

Despite this earlier identification of SH3TC2, Lupski had never been able to

verify that the gene was in fact the source of his CMT. " We had sent my DNA

sample to the laboratories involved in the gene discovery of SH3TC2 and its

association with CMT, but the screening methods used at the time apparently

failed to identify the mutations, " he said.

" Some people say, well, the gene was known before. It's nothing new. That's a

correct statement, but it certainly hadn't been found in me, " Lupski continued.

" The gene in my family had not been found, and we tried for 20 years to find it.

It wasn't until we tried this approach that we found the gene, and for that

reason we shouldn't take away from the scientific achievement. "

Ushering in a new era

Prior to the sequencing of Lupski's genome, all the other genomes that had been

sequenced were in individuals with no disease phenotype (observable physical or

biochemical characteristics), and the differences were attributable to simple

variation, Lupski explained.

" We've demonstrated for the first time that you can take an individual's genome

and actually find a clinically relevant, medically actionable, stretch of DNA, "

he said. The opportunity then exists to take clinical action based on what is

found.

Lupski believes that's " the key, " and that the ability to glean such clinically

important, usable information to help individuals affected by genetic disease is

going to be the " future of medicine. "

" It's why we've all worked so hard to move these technologies forward, " he

explained. " It took 15 years to get the original human genome sequenced, and

now, on a machine, we can pump out the raw data in a few days. And that

interval's going to become shorter and shorter. "

The biggest bottleneck right now in the application of human genome sequencing

to clinical medicine is the analysis, Lupski said.

" It's analyzing the data to know and interpret what it means, and here we're

going to need computational power that many places are not quite capable of yet.

So the field will also move forward as the computational field moves forward. "

Cost decreasing

Lupski believes individual DNA sequencing eventually will become a routine part

of the diagnostic process, particularly as the cost of whole genome sequencing

goes down.

" We had to guesstimate for the [scientific] journal what it cost to do my

genome, and in the end we had to say that it was approximately $50,000, " Lupski

said. " If we had repeated the experiment at the time of submission, it would

have been down to $15,000. If we repeated the experiment now, it's below

$10,000. We believe within two years it will be below $8,000, and everybody is

working toward the $1,000 genome. "

As part of that effort, the National Human Genome Research Institute (NHGRI) in

September 2010 awarded 10 grants, totaling more than $18 million, tagged for the

development of new technologies aimed at reaching that $1,000-per-genome cost.

'We've all been dealt a hand of cards'

Diseases arise via a number of different causes, many of them genetic, with more

genetic susceptibilities or causes being found all the time.

" So we all have this hand of cards we've been dealt — and to what extent will

that play a role in determining the best therapy for us as individuals? " Lupski

said. " That's what the goal of personalized medicine is, and it's what we wanted

to show. "

Lupski noted that currently, for a cost of around $8,000, someone with CMT can

order a full-panel genetic test of the approximately 20 CMT-associated genes

available for clinical testing (tests are not yet available for all the known

genes).

" So the question is, do you order a panel that can test 20 CMT genes for $8,000,

or do you get the whole genome for $5,000? " he asked.

" If you actually get the cost to $1,000, it's going to be cheaper than a CT

scan. It may be that the first thing a physician wants to do is see what hand of

cards you've been dealt. "

Lupski contrasted what he termed the current " one-size-fits-all " medical

practice to what " we've known all along in pediatrics. "

Pediatrics, he said, is one of the only specialties where prescriptions are

based on the size and weight of the patient. In most cases, adults, whether

they're 18 or 65, receive the same prescription. Individualized considerations,

such as whether one is a fast or slow metabolizer, aren't usually taken into

account.

New technology, including whole-genome sequencing, is poised to help change

that.

" With personalized medicine, we will actually start tailoring the therapy to the

individual patient rather than the individual disease, " Lupski said. " That's

what personalized medicine is all about; there's no such thing as one size fits

all. "